Overview
A new name just joined the short list of weight loss drugs with completed phase 3 results. On November 15, 2026, the full results of the GEMINI-1 trial of ribupatide — a once-weekly dual GLP-1/GIP injection developed by China's Hengrui Pharma and licensed to Boston-based Kailera Therapeutics — were published in JAMA, timed to ObesityWeek 2026. Patients on the highest dose lost 17.7% of their body weight on average in 48 weeks, and nearly half of them lost 20% or more.
If you are weighing treatment options today, ribupatide is not something you can get — it is not approved anywhere yet, and it is not available in the United States. But these results matter for anyone on, or considering, a GLP-1: they confirm that the pipeline behind semaglutide and tirzepatide keeps getting deeper, and more competition is one of the few forces that reliably pushes prices and access in patients' favor.

